Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
- None.
- None.
Insights
The recent publication detailing the liver safety profile of AD04 presents a notable development in the treatment of Alcohol Use Disorder (AUD). The focus on a specific 5-marker genetic profile suggests a move towards personalized medicine, which could lead to more effective treatments with fewer side effects. The absence of significant changes in liver biochemical markers such as ALT, AST and Serum Bilirubin indicates that AD04 could be a viable option for patients with AUD, particularly considering the high incidence of alcohol-associated liver disease (ALD) in this population.
The reported high medication compliance and low dropout rates are significant metrics that could predict the commercial success of AD04, as they suggest the drug is not only safe but also user-friendly. This could lead to better patient outcomes and potentially lower healthcare costs due to reduced complications from AUD and ALD.
From an economic perspective, the introduction of AD04 by Adial Pharmaceuticals could disrupt the current market for AUD treatments, which is characterized by limited options with low efficacy and poor adherence. The emphasis on safety and tolerability could position AD04 favorably among healthcare providers and patients, potentially leading to rapid market penetration and adoption upon successful completion of clinical trials and regulatory approval.
Furthermore, the potential reduction in alcohol-related liver damage could translate into significant cost savings for healthcare systems, given the high cost associated with liver disease management and transplantation. The precision treatment approach may also result in more efficient resource allocation in healthcare, as treatments could be targeted to those most likely to benefit, thereby improving the overall cost-effectiveness of AUD management.
The peer-reviewed publication serves as a validation of Adial Pharmaceuticals' research and development efforts in the biotech industry, particularly within the niche of addiction treatment. The unique safety profile of AD04 as comparable to placebo, especially in a field where effective medications often come with significant adverse effects, sets a new standard that could influence future drug development in this area.
It is also important to note that the company's stock performance (NASDAQ: ADIL) may respond positively to these findings, as investors typically look for indicators of potential market success in clinical trial results. The fact that this study has been published in a reputable journal adds credibility to the findings and may attract further investment. However, investors will also be vigilant about the drug's progress through the remaining clinical trial phases and the regulatory review process, as these are critical hurdles that will ultimately determine the drug's commercial viability.
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial
GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company’s lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD). The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with placebo in subjects with AUD in the Company’s prior Phase 3 clinical trial.
The published study provides a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5-marker genetic profile. AUD, characterized by compulsive alcohol consumption and loss of control over intake, poses significant health risks and is a major contributor to alcohol-associated liver disease (ALD), a leading cause of liver transplantation and global mortality.
According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin. Additionally, while patients with AUD displayed elevated GGT levels, typically associated with increased alcohol consumption, this parameter remained unaffected by low-dose AD04. Additionally, no significant adverse effects were observed due to oral low-dose AD04 treatment. The publication also highlighted that low-dose AD04 demonstrated an outstanding safety and tolerability profile compared to placebo, featuring a low occurrence of adverse events (AEs), high medication compliance, and a minimal dropout rate. The authors further noted that there is no existing study in alcohol literature where an effective medication exhibits a similar AE profile to a placebo.
The manuscript entitled, “Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment,” was published in the European Journal of Internal Medicine. The publication is available via Open Access at: https://www.ejinme.com/article/S0953-6205(24)00123-7/fulltext
Cary Claiborne, CEO of Adial, commented, “Current pharmacological treatments for AUD are limited by low efficacy, poor adherence and adverse effects. This peer-reviewed publication emphasizes the safety and potential of AD04 in addressing the critical needs of individuals suffering from AUD and ALD. With this significant milestone, we are one step closer to providing a precision treatment option that could make a profound impact on the lives of millions worldwide.”
“This study report further supports prior data showing that AD04 treatment does not pose significant health risks in patients with AUD. AD04 was well tolerated, and no treatment related serious adverse events were observed. AD04 treatment was not associated with significant changes in liver biochemical parameters, cardiac events, or general well-being. Most importantly, the publication highlighted the potential of AD04 for the treatment for AUD among patients with a specified genetic background. Ultimately, we believe AD04 could pave the way for precision treatments tailored to individuals with AUD, offering a novel strategy to not only manage alcohol consumption but also mitigate liver damage in affected populations,” concluded Claiborne.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Forward-Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding peer-reviewed publication highlighting the promising results, safety, and high patient compliance of AD04 as a potential treatment for alcohol use disorder. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to retain our key employees or maintain our Nasdaq listing, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
FAQ
What is the focus of Adial Pharmaceuticals' lead investigational new drug product AD04?
What were the key findings of the peer-reviewed article on AD04?
What did the publication report regarding the liver safety profile of AD04 in individuals with AUD?
Where was the manuscript entitled 'Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment' published?
What did Cary Claiborne, CEO of Adial, emphasize regarding the potential of AD04 for treating AUD?
